{
  "nctId": "NCT03422848",
  "briefTitle": "Hydration to Optimize Metabolism",
  "officialTitle": "Hydration to Optimize Metabolism",
  "protocolDocument": {
    "nctId": "NCT03422848",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2017-12-15",
    "uploadDate": "2018-01-29T10:30",
    "size": 409955,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03422848/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 760,
    "enrollmentType": "ESTIMATED"
  },
  "timeline": {
    "startDate": "2018-04-24",
    "completionDate": "2025-06-30",
    "primaryCompletionDate": "2025-05-23",
    "firstSubmitDate": "2018-01-06",
    "firstPostDate": "2018-02-06"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Provision of informed consent, age 20-75 years with high plasma concentration of vasopressin (plasma concentration of copeptin of \\> 6.1 pmol/L in women and \\> 10.7 pmol/L in men) and 24 hour urine osmolality \\> 600 milliosmol (mOsm) /kg water.\n\nExclusion Criteria:\n\n* 24 hour urine volume \\> 1.5 L, pregnancy or breastfeeding, plasma sodium \\< 135 mmol/L, use of diuretics, lithium or selective serotonin reuptake inhibitor (SSRI) drugs, chronic kidney disease (estimated glomerular filtration rate \\< 30 mL/min), heart failure, inflammatory bowel disease, type 1 diabetes or type 2 diabetes treated with insulin, vulnerable subjects (subjects with legal guardian, with loss of personal liberty).",
    "healthyVolunteers": true,
    "sex": "ALL",
    "minimumAge": "20 Years",
    "maximumAge": "75 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Fasting plasma glucose concentration (mmol/L)",
        "description": "Difference in change of fasting plasma glucose between water intervention arm and control arm.",
        "timeFrame": "12 months"
      }
    ],
    "secondary": [
      {
        "measure": "Diabetes incidence",
        "description": "Difference in diabetes incidence between water intervention arm and control arm.",
        "timeFrame": "12 months"
      },
      {
        "measure": "Post oral glucose load glucose concentration (mmol/L)",
        "description": "Difference in change of post oral glucose load glucose concentration (mmol/L) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "Fasting insulin concentration (mIE/L)",
        "description": "Difference in change of fasting insulin (mIE/L) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "Post oral glucose load insulin concentration (mIE/L)",
        "description": "Difference in change of post oral glucose load insulin concentration (mIE/L) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "Fasting glucagon concentration (pmol/L)",
        "description": "Difference in change of fasting glucagon (pmol/L) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "Post oral glucose load glucagon concentration (pmol/L)",
        "description": "Difference in change of post oral glucose load glucagon concentration (pmol/L) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "HbA1c concentration (mmol/mol)",
        "description": "Difference in change of HbA1c (mmol/mol) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "Waist circumference (cm)",
        "description": "Difference in change of waist circumference (cm) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "Body mass index (kg/m^2)",
        "description": "Difference in change of body mass index (kg/m\\^2) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "Systolic blood pressure (mmHg)",
        "description": "Difference in change of systolic blood pressure (mmHg) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "Diastolic blood pressure (mmHg)",
        "description": "Difference in change of diastolic blood pressure (mmHg) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "Triglyceride concentration (mmol/L)",
        "description": "Difference in change of triglycerides (mmol/L) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "HDL cholesterol concentration (mmol/L)",
        "description": "Difference in change of HDL cholesterol (mmol/L) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "LDL cholesterol concentration (mmol/L)",
        "description": "Difference in change of LDL cholesterol (mmol/L) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "Apolipoprotein B concentration (g/L)",
        "description": "Difference in change of Apolipoprotein B (g/L) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "Apolipoprotein A1 concentration (g/L)",
        "description": "Difference in change of Apolipoprotein A1 (g/L) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "Urine albumin/creatinine ratio (g/mol)",
        "description": "Difference in change of urine albumin/creatinine ratio (g/mol) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "Estimated glomerular filtration rate (mL/min/1,73 m2)",
        "description": "Difference in change of estimated glomerular filtration rate (mL/min/1,73 m2) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "Creatinine clearance (mL/min)",
        "description": "Difference in change of creatinine clearance (mL/min) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "Fasting cortisol concentration (nmol/L)",
        "description": "Difference in change of fasting cortisol (nmol/L) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "Fasting adrenocorticotropic hormone concentration (pmol/L)",
        "description": "Difference in change of fasting adrenocorticotropic hormone (pmol/L) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "C-reactive protein concentration (mg/L)",
        "description": "Difference in change of C-reactive protein (mg/L) between water intervention arm and control arm",
        "timeFrame": "12 months"
      },
      {
        "measure": "Hair cortisol concentration (pg/mg)",
        "description": "Difference in change of hair cortisol (pg/mg) between water intervention arm and control arm. Hair cortisol is a measure of chronic stress exposure 3 months prior to sampling.",
        "timeFrame": "12 months between samplings"
      }
    ],
    "other": [
      {
        "measure": "Fasting plasma glucose concentration in pre-specified subgroups",
        "description": "glucose reduction in A) subjects who remain high in copeptin from population screening to main study baseline, B) subjects with the highest (top tertile) baseline copeptin, C) subjects with/without diabetes mellitus at baseline, D) subjects with/without impaired fasting glucose (diabetes+impaired/not impaired), E) men and women separately.",
        "timeFrame": "12 months"
      }
    ]
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 23,
      "otherCount": 1,
      "totalCount": 25
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:06.474Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}